Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lilly/Innovent Assess New US Trial After PD-1 Rejected by FDA

publication date: Mar 24, 2022

Eli Lilly reported the US FDA formally rejected its anti-PD-1 antibody sintilimab, which it partners with China’s Innovent Pharma. The rejection was expected after the advisory committee voted almost unanimously against approval last month. Lilly-Innovent was seeking approval of the PD-1 as a first-line therapy for nonsquamous non-small cell lung cancer. Lilly did not immediately say it would conduct a new Phase III trial in the US. Instead, the company said it was assessing the US situation together with Innovent. More details....

Stock Symbols: (NYSE: LLY) (HK: 01801)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital